BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 22091681)

  • 1. Use of allogeneic NK cells for cancer immunotherapy.
    Geller MA; Miller JS
    Immunotherapy; 2011 Dec; 3(12):1445-59. PubMed ID: 22091681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting natural killer cells in cancer immunotherapy.
    Guillerey C; Huntington ND; Smyth MJ
    Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells and cancer therapy, what we know and where we are going.
    Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
    Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell therapies.
    Vivier E; Rebuffet L; Narni-Mancinelli E; Cornen S; Igarashi RY; Fantin VR
    Nature; 2024 Feb; 626(8000):727-736. PubMed ID: 38383621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
    Luevano M; Madrigal A; Saudemont A
    Cell Mol Immunol; 2012 Jul; 9(4):310-20. PubMed ID: 22705914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of cancer therapy with natural killer cells.
    Klingemann H
    Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell immunotherapy for cancer: a new hope.
    Srivastava S; Lundqvist A; Childs RW
    Cytotherapy; 2008; 10(8):775-83. PubMed ID: 19089686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
    Davis ZB; Vallera DA; Miller JS; Felices M
    Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
    Daher M; Rezvani K
    Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology of natural killer cells and implications for therapy of human disease.
    Chiorean EG; Miller JS
    J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
    Mantesso S; Geerts D; Spanholtz J; Kučerová L
    Front Immunol; 2020; 11():607131. PubMed ID: 33391277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cell-based cancer immunotherapy: from basic biology to clinical application.
    Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
    Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
    Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
    Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.